About GT Biologics
GT Biologics is a Healthcare company based in Shoreview (United States) founded in 2007 by Denise Kelly, and was acquired by 4D pharma in June 2014. Developing naturally occurring human bacteria as biotherapeutics for gastrointestinal diseases. The company was acqui-hired. Its focus areas include Life Sciences, Microbiome Therapeutics, Probiotics and Gastroenterology. Its competitors include Ironwood Pharma, Evelo Biosciences and Alcresta; 3 of its 3 listed competitors have raised funding.
Company details
GT Biologics was founded in 2007 and is based in Shoreview, United States. Operations focus on the biotechnology sector, where naturally occurring human bacteria are developed into biotherapeutics targeting gastrointestinal diseases such as Crohns disease. Intellectual property has been established around specific bacterial strains. The lead product remains in preclinical development for Crohns disease treatment.
- Headquarters Shoreview, United States
- Founders Denise Kelly
- Stage Acquired
- SectorsHealthcare
- Website gt-biologics.com
- Social LinkedIn
- Acquired by 4D pharma (Jun 2014)
Funding Insights of GT Biologics
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of GT Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2012 | Series A | – | – |
2 investors in total: 2 institutional.
Investors in GT Biologics
GT Biologics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include 4D pharma and Aquarius Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Science focused VC firm investing in the US & UK | aquariusequity.com | Manchester, United Kingdom | ||
Drugs from gut bacteria are developed for multiple diseases. | 2008 | 4dpharmaplc.com | Manchester, United Kingdom |
Investor details for GT Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GT Biologics
1 people are tracked at GT Biologics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Denise Kelly | Founder | Leadership |
Complete people profiles for GT Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GT Biologics
3 dated milestones of GT Biologics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded GT Biologics is founded.
- Funding First funding round.
- Exit Acquired by 4D pharma.
Competitors of GT Biologics
GT Biologics has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Evelo Biosciences and Alcresta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| evelobio.com | 2015 | Cambridge, United States | $166.5M | 117 | Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. |
Detailed competitors of GT Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Microbiome Therapeutics
3 companies that operate in the same segment as GT Biologics (Microbiome Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | 55 | ||
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | 12 | ||
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GT Biologics
GT Biologics was founded in 2007 and raised its 1st funding round 5 years after it was founded.
GT Biologics is headquartered in Shoreview, United States. It is registered at Shoreview, Minnesota, United States.
GT Biologics was founded in 2007 and is based in Shoreview, United States. Operations focus on the biotechnology sector, where naturally occurring human bacteria are developed into biotherapeutics targeting gastrointestinal diseases such as Crohns disease. Intellectual property has been established around specific bacterial strains. The lead product remains in preclinical development for Crohns disease treatment.
GT Biologics's top competitors include Ironwood Pharma, Alcresta and Evelo Biosciences.
GT Biologics has 2 investors. Key investors include 4D pharma, and Aquarius Equity Partners.
Yes. GT Biologics was acquired by 4D pharma in June 2014.